Suchergebnisse - "Armuzzi, Alessandro"

PubPharm (427)

71

Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries

enthalten in: BMC gastroenterology | 2023

von Armuzzi, A. | Hart, A. | Cappelleri, J. | +6

72

Improvements in Disease Activity Partially Mediate the Effect of Tofacitinib Treatment on Generic and Disease-Specific Health-Related Quality of Life in Patients with Ulcerative Colitis : Data from the OCTAVE Program

enthalten in: Digestive diseases (Basel, Switzerland) | 2023

von Dubinsky, M. | Armuzzi, A. | Gecse, K. | +7

73

Dysfunctional Extracellular Matrix Remodeling Supports Perianal Fistulizing Crohn's Disease by a Mechanoregulated Activation of the Epithelial-to-Mesenchymal Transition

enthalten in: Cellular and molecular gastroenterology and hepatology | 2023

von Rizzo, G. | Rubbino, F. | Elangovan, S. | +22

CommentIn: Cell Mol Gastroenterol Hepatol. 2023;15(3):801-802. - PMID 36586719

74

Comparison of two strategies for the management of postoperative recurrence in Crohn’s disease patients with one clinical risk factor : A multicentre IG‐IBD study

enthalten in: United European Gastroenterology Journal | 2023

von Dragoni, G. | Castiglione, F. | Bezzio, C. | +18

75

The role of ustekinumab and vedolizumab in management of extra intestinal manifestations in inflammatory bowel disease

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2023

von Katsanos, K. | Fousekis, F. | Armuzzi, A.

CommentOn: Dig Liver Dis. 2023 Feb;55(2):223-229. - PMID 36241535

76

Patient-Reported Outcomes for the Assessment of Sexual Health Among Patients Affected by Inflammatory Bowel Disease

enthalten in: Reviews on recent clinical trials | 2022

von Pugliese, D. | Parisio, L. | Schepis, T. | +4

77

Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease : A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy

enthalten in: Journal of gastrointestinal and liver diseases : JGLD | 2022

von Tursi, A. | Mocci, G. | Cuomo, A. | +89

78

Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn's Disease : A Pooled Analysis of 6 Trials

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2022

von Beelen, E. | Nieboer, D. | Arkenbosch, J. | +8

79

Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab : A Real-World Multicentre European Study

enthalten in: Journal of Crohn's & colitis | 2022

von Yanai, H. | Kagramanova, A. | Knyazev, O. | +68

80

Letter to the Editor

enthalten in: Journal of Crohn's & colitis | 2022

von ECCO Governing Board | Peyrin-Biroulet, L. | Siegmund, B. | +5

CommentOn: J Crohns Colitis. 2010 Nov;4(5):523-31. - PMID 21122555